

CITATION REPORT

List of articles citing

Side effects of medical therapy for chronic hepatitis C

DOI: PM/15118573

Annals of Hepatology, 2004, 3, 5-10.

Source: <https://exaly.com/paper-pdf/132539692/citation-report.pdf>

Version: 2024-04-20

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
11	Chronic hepatitis C: treatment of pegylated interferon/ribavirin nonresponders. <i>Current Gastroenterology Reports</i> , 2006 , 8, 46-52	5	17
10	Chronic hepatitis C: Treatment of pegylated interferon/ ribavirin nonresponders. <i>Current Hepatitis Reports</i> , 2006 , 5, 114-120		
9	Exploring drug users' attitudes and decisions regarding hepatitis C (HCV) treatment in the U.S. <i>International Journal of Drug Policy</i> , 2008 , 19, 71-8	5.5	39
8	Evaluation of oral cannabinoid-containing medications for the management of interferon and ribavirin-induced anorexia, nausea and weight loss in patients treated for chronic hepatitis C virus. <i>Canadian Journal of Gastroenterology & Hepatology</i> , 2008 , 22, 376-80		20
7	A study of best positive predictors for sustained virologic response to interferon alpha plus ribavirin therapy in naive chronic hepatitis C patients. <i>BMC Gastroenterology</i> , 2009 , 9, 5	3	47
6	Pityriasis rosea associated with pegylated interferon alfa and ribavirin treatment in a patient with chronic hepatitis C. <i>Balkan Medical Journal</i> , 2013 , 30, 253-4	1.5	2
5	Meta-Analysis of Combination Therapy of Chinese Herbs Plus Interferon and Ribavirin in Patients with Chronic Hepatitis C. <i>Medical Science Monitor</i> , 2016 , 22, 1817-26	3.2	3
4	Clinical Evaluation of Terap C Vaccine in Combined Treatment with Interferon and Ribavirin in Patients with Hepatitis C. <i>Current Therapeutic Research</i> , 2017 , 85, 20-28	2.4	1
3	Engagement in the Hepatitis C care continuum among people who use drugs. <i>Journal of Substance Use</i> , 2020 , 25, 343-349	0.8	0
2	Insights to SARS-CoV-2 life cycle, pathophysiology, and rationalized treatments that target COVID-19 clinical complications. <i>Journal of Biomedical Science</i> , 2021 , 28, 9	13.3	52
1	The practical management of treatment failure in chronic hepatitis C: a summary of current research and management options for refractory patients. <i>Gastroenterology and Hepatology</i> , 2007 , 3, 4-32	0.7	2